Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

Takeda Presents Additional Data from theTakeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session PR Newswire WASHINGTON and OSAKA, Japan, March 27, 2014 -- Sub-analyses Investigate the Effects of alogliptin on Cardiovascular Mortality Rates and Hospitalization for Heart Failure in Type 2 Diabetes Patients with Recent Acute Coronary Syndrome Takeda Pharmaceutical Company Limited (Takeda) will present sub- analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial in a poster session at the American College of rdCardiology's (ACC) 63 Annual Scientific Session in Washington, DC. These sub-analyses specifically investigated the effects of the dipeptidyl peptidase-4 inhibitor (DPP-4i) alogliptin on rates of CV mortality and hospitalization for heart failure (HF). Alogliptin is the first and only DPP-4i to demonstrate CV safety outcomes in Type 2 diabetes patients with recent acute coronary syndrome (ACS). Heart disease, or cardiovascular disease (CVD), is the leading cause of morbidity and mortality in patients with Type 2 diabetes, and is responsible for between 50 and 80 percent of deaths in people with diabetes.